Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 18/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434841 | 0.90 | MKNK2 (0.57) | MKNK2MKNK1BRAFTNNI3KPIP4K2C | |
| SCHEMBL15101111 | 0.90 | MKNK2 (0.43) | MKNK2MKNK1BRAFTNNI3KPIP4K2C | |
| SCHEMBL13434875 | 0.86 | MKNK2 (0.50) | MKNK2MKNK1 | |
| SCHEMBL3803982 | 0.85 | MKNK2 (0.51) | MKNK2MKNK1 | |
| SCHEMBL3797939 | 0.80 | MKNK2 (0.56) | MKNK2MKNK1 | |
| SCHEMBL15428425 | 0.80 | MKNK2 (0.45) | MKNK2MKNK1BRAFTNNI3KPIP4K2C | |
| SCHEMBL13434840 | 0.79 | MKNK2 (0.45) | MKNK2MKNK1BRAFTNNI3KPIP4K2C | |
| SCHEMBL13434842 | 0.78 | MKNK2 (0.44) | MKNK2MKNK1BRAFTNNI3KPIP4K2C | |
| SCHEMBL3801021 | 0.78 | MKNK2 (0.66) | MKNK2MKNK1 | |
| SCHEMBL13402702 | 0.77 | MKNK2 (0.53) | MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| EP-2004656-B1 | THIENOPYRIMIDINES HAVING MNK1 /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-10 | — | — | EP | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| WO-2007115822-A1 | THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | CMPK1, DTYMK, NEK9 | MKNK2 8/4885MKNK1 29/4885BRAF 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.